Targeting cancer with Click Chemistry

Less than 1% of administered drugs make it to their desired location in the body.

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC®) platform is a pre-targeting approach, capturing payloads at the tumor via in-vivo click chemistry, a  2022 Nobel Prize-winning technology.

We are the first company to use click chemistry in patients.

CAPAC is modular

CAPAC separates the binder from the payload and reunites them at the tumor.
Clickable binder
Binds selectively to the tumor
Clickable payload
Either a radioisotope or  cancer drug that is inert until it clicks with the binder at the tumor

Activation

When the systemically administered clickable payload reaches the clickable binder at the tumor, a click chemistry reaction takes place. For radioisotopes, this locks the radioisotope at the tumor; for chemotherapy this activates the payload.

Changing what's possible

We separate tumor targeting from the payload, and rely on chemistry, not biology, for activation. This leads to maximum active payload at the tumor and lower systemic toxicity than has been previously possible.

CAPAC is designed to expand the scope of potential targets and widen the therapeutic window of antibody drug conjugates (ADCs) and targeted radiopharm approaches. CAPAC has been validated in the clinic and we are rapidly advancing novel therapies for patients with limited effective treatment options.
Our platform

Latest News

October 1, 2025
press
Shasqi Appoints Former Pfizer Oncology Leader to Board
  • Roger Dansey, M.D., a former senior executive at Pfizer and Seagen, brings extensive experience in oncology clinical development and the development of antibody-drug conjugates (ADCs) and other targeted cancer therapies.

SAN FRANCISCO, Oct. 1, 2025 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with pre-targeting enabled by click chemistry, today announced the appointment of Roger Dansey, M.D., a prominent leader in oncology research and drug development, to its Board of Directors.

Dr. Dansey most recently served as the Chief Development Officer and interim Chief Oncology Officer at Pfizer Oncology. Prior to this, he was Chief Medical Officer and President of Research and Development at Seagen Inc., a company known for pioneering and commercializing ADCs. Over the last 20 years Roger has contributed significantly to the clinical development and multiple approvals of important cancer medicines such as Xgeva®/Prolia® (denosumab), Zydelig® (idelalisib), Keytruda® (pembrolizumab), Adcetris® (brentuximab Vedotin), Padcev® (enfortumab vedotin), Tivdak® (tisotumab vedotin) and Tukysa® (tucatinib).

"Roger brings his exceptional leadership in oncology to our Board at a pivotal moment. Most importantly, Roger's deep expertise in the development of ADCs from his tenure at Seagen and Pfizer will be invaluable as we bring our lead asset to the clinic and grow our pipeline of pre-targeted cancer therapeutics," said Shasqi CEO and Founder, José M. Mejía Oneto, M.D., Ph.D.

"I'm delighted to join the Shasqi team and Board of Directors to advance their pre-targeting technology. This pioneering approach has real potential to benefit patients by getting more drug directly to tumors and improving efficacy - without the dose-limiting toxicities of current therapies," said Dr. Dansey.

Together we can transform cancer treatment

Ready to help us develop the future of cancer therapies?
Interested in exploring a collaboration?